搜索
Rxsight Inc
RXST添加自选
5.610USD
+0.440+8.51%
收盘 07/02, 13:00（美东）报价延迟15分钟
232.23M总市值
亏损市盈率 TTM
关键数据
5.140今开
5.670最高
3.55M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
8.61%换手率
5.170昨收
5.140最低
17.57M成交额
亏损市盈率静
0.84市净率
0.00%股息率 TTM
-15.12%ROA
26.38052周最高
2.65量比
-27.45M净利润
41.24M总股本
-1.1357每股收益TTM
1.21Beta
-17.06%ROE
5.90052周最低
10.24%振幅
76.06%毛利率
232.23M总市值
1.95回报/风险
4.07%风险率
TradingKey Rxsight Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Rxsight Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名83/204位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价8.93。中期看，股价处于下降通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Rxsight Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Rxsight Inc亮点
亮点风险
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
业绩高增长
公司营业收入稳步增长，连续3年增长50.97%
估值高估
公司最新PE估值-4.94，处于3年历史高位
机构减仓
最新机构持股38.60M股，环比减少22.17%
活跃度增加
近期活跃度增加，过去20天平均换手率0.55
分析师目标
根据
10
位分析师
持有
评级
8.929
目标均价
+75.07%
涨幅空间
Rxsight Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Rxsight Inc简介
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
公司代码RXST
公司Rxsight Inc
CEOKurtz (Ron M)
网址https://www.rxsight.com/
相关品种
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+3.50%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
+0.28%热门品种
常见问题
Rxsight Inc(RXST)的当前股价是多少？
Rxsight Inc(RXST)的当前股价是 5.61。
Rxsight Inc的股票代码是什么？
Rxsight Inc的股票代码是RXST。
Rxsight Inc股票的52周最高点是多少？
Rxsight Inc股票的52周最高点是26.38。
Rxsight Inc股票的52周最低点是多少？
Rxsight Inc股票的52周最低点是5.90。
Rxsight Inc的市值是多少？
Rxsight Inc的市值是231.37M。
现在Rxsight Inc(RXST)的股票是买入、持有还是卖出？
根据分析师评级，Rxsight Inc(RXST)的总体评级为signal_hold，目标价格为8.93。
Rxsight Inc(RXST)股票的每股收益（EPS TTM）是多少
Rxsight Inc(RXST)股票的每股收益（EPS TTM）是-0.95。